NOVACYT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.788 EUR | -1.13% |
|
+0.13% | +10.52% |
| 05-01 | Novacyt Says UK Court Dismissed Government's Summary Judgment Application | MT |
| 05-01 | Novacyt notes court dismissal of UK DHSC summary judgment application | AN |
| Sales 2021 | 95.78M 103M 8.24B | Sales 2022 | 21.04M 22.66M 1.81B | Capitalization | 76.79M 82.69M 6.61B |
|---|---|---|---|---|---|
| Net income 2021 | -9M -9.69M -774M | Net income 2022 | -25M -26.92M -2.15B | EV / Sales 2021 | 1.67 x |
| Net cash position 2021 | 99.9M 108M 8.6B | Net cash position 2022 | 86.29M 92.93M 7.42B | EV / Sales 2022 | -0.45 x |
| P/E ratio 2021 |
-26.3
x | P/E ratio 2022 |
-2.99
x | Employees | 120 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 96.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novacyt
More news
| 1 day | -1.13% | ||
| 1 week | +0.13% | ||
| Current month | -5.17% | ||
| 1 month | +30.46% | ||
| 3 months | +38.37% | ||
| 6 months | +30.03% | ||
| Current year | +10.52% |
1 week
0.75
0.80
1 month
0.580.88
Current year
0.490.88
1 year
0.421.00
3 years
0.425.89
5 years
0.0613.96
10 years
0.0613.96
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Gibson
DFI | Director of Finance/CFO | 41 | 31/03/17 |
Paul Oladimeji
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/16 |
James McCarthy
BRD | Director/Board Member | 58 | 04/01/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Brown
BRD | Director/Board Member | 69 | 07/09/23 |
Lyn Rees
CEO | Chief Executive Officer | 51 | 07/09/23 |
| Chairman | 58 | 30/09/14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 0.788 | -1.13% | 87,302 |
| 09/05/24 | 0.797 | +3.78% | 79,602 |
| 08/05/24 | 0.768 | -0.26% | 74,386 |
| 07/05/24 | 0.77 | -0.13% | 96,514 |
| 06/05/24 | 0.771 | -2.03% | 140,447 |
Real-time Euronext Paris, May 10, 2024 at 04:35 pm
More quotes
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors:
- development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
- manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
Calendar
25/09/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +10.52% | 59.9M | |
| -15.05% | 1.1B | |
| -22.03% | 126M | |
| +3.72% | 75.91M | |
| +5.15% | 60.02M | |
| -1.20% | 51.7M |
- Stock Market
- Equities
- ALNOV Stock
